Home › Research › TREM2 and immune genetics
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Bancaro N, Calì B, Troiani M, Elia AR, Arzola RA, Attanasio G, Lai P, Crespo M et al.. Cancer cell, 2023-03-02
Topic: Brain proteins, microglia and lab models
Tumor cells promote the recruitment of immunosuppressive neutrophils, a subset of myeloid cells driving immune suppression, tumor proliferation, and treatment resistance. Physiologically, neutrophils are known to have a short half-life. Here, we report the identification of a subset of neutrophils that have upregulated expression of cellular senescence markers and persist in the tumor microenvironment.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bancaro, N., Calì, B., Troiani, M., Elia, A. R., Arzola, R. A., Attanasio, G., et al. (2023). Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer cell. https://doi.org/10.1016/j.ccell.2023.02.004
Vancouver
Bancaro N, Calì B, Troiani M, Elia AR, Arzola RA, Attanasio G, et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer cell. 2023. doi:10.1016/j.ccell.2023.02.004. PMID: 36868226.
BibTeX
@article{bancaro2023-36868226,
author = {Bancaro, N. and Calì, B. and Troiani, M. and Elia, A. R. and Arzola, R. A. and Attanasio, G. and Lai, P. and Crespo, M. and others},
title = {{Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer}},
journal = {Cancer cell},
year = {2023},
doi = {10.1016/j.ccell.2023.02.004},
pmid = {36868226},
url = {https://doi.org/10.1016/j.ccell.2023.02.004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Physiologically, neutrophils are known to have a short half-life.
- Here, we report the identification of a subset of neutrophils that have upregulated expression of cellular senescence markers and persist in the tumor microenvironment.
- Senescent-like neutrophils express the triggering receptor expressed on myeloid cells 2 (TREM2) and are more immunosuppressive and tumor-promoting than canonical immunosuppressive neutrophils.
- Genetic and pharmacological elimination of senescent-like neutrophils decreases tumor progression in different mouse models of prostate cancer.
Why it matters
This study identified senescent-like neutrophils expressing TREM2 that promote tumors and suppress immunity in prostate cancer. It is about cancer, not Alzheimer's, and provides no information about treating, curing or preventing Alzheimer's.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cancer cell) |
| Journal's citation record | 3 / 4 | Cancer Cell: journal h-index 485 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 178 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 35.6 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 4 / 6 | Cited 15.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 168 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Andrea Alimonti: h-index 52 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | ETH Zurich: institution h-index 1,286 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36868226) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics
Also tagged “mice”
1,150 studies in the library carry the topic tag “mice”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.